TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
Novo Nordisk Pharmatech A/S
Closing information (x1000 NOK)
| Closing information | 2025/12 | 2024/12 | 2023/12 |
| Turnover |
1,518,119
|
1,327,835 | |
| Earnings before taxes |
122,741
|
148,848 | |
| Total assets |
3,116,643
|
1,910,252 | |
| Current assets |
1,495,370
|
954,577 | |
| Current liabilities |
942,522
|
691,438 | |
| Equity capital |
2,108,175
|
1,156,671 | |
| - share capital |
15,883
|
15,084 | |
| Employees (average) |
150
|
150
|
150 |
Financial ratios
| Fiscal year | 2025/12 | 2024/12 | 2023/12 |
| Solvency |
67.6%
|
60.6% | |
| Turnover per employee |
10,121
|
8,852 | |
| Profit as a percentage of turnover |
8.1%
|
11.2% | |
| Return on assets (ROA) | |||
| Current ratio |
158.7%
|
138.1% | |
| Return on equity (ROE) |
5.8%
|
12.9% | |
| Change turnover |
120,100
|
425,521 | |
| Change turnover % |
9%
|
9%
|
47% |
| Chg. No. of employees |
0
|
0
|
0 |
| Chg. No. of employees % |
0%
|
0%
|
0% |
Total value of public sale
| Fiscal year | 2025/12 | 2024/12 | 2023/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.